Shanghai Yingli Pharmaceutical Co. Ltd. has divulged phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
Nanjing Zaiming Pharmaceutical Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Almirall SA has disclosed tyrosine-protein kinase ITK/TSK (EMT) inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis, alopecia areata, vitiligo, T-cell lymphoma, asthma, inflammatory bowel disease and multiple sclerosis, among others.
Merck Sharp & Dohme LLC and Peloton Therapeutics Inc. have described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Eubulus Biotherapeutics Inc. has identified molecular glue degraders acting as cyclin-dependent kinase 2 (CDK2) degradation inducers reported to be useful for the treatment of cancer.
University of Notre Dame du Lac has disclosed peptide-drug conjugates, their hydrogels and their self-assembling nanofibers comprising glucagon-like peptide 1 receptor (GLP-1R) and/or gastric inhibitory polypeptide receptor (GIPR) and/or glucagon receptor agonists linked to an amphiphile moiety through a hydrophobic or hydrophilic-comprising linker acting as vaccine adjuvants reported to be useful for the treatment of diabetes and obesity.
South Korea’s Ministry of Food and Drug Safety announced Sept. 12 plans to significantly raise drug application fees for biosimilars but slash their review times starting next year.
RSS
